|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
Development, Vol 126, Issue 7 1407-1415, Copyright © 1999 by Company of Biologists
JOURNAL ARTICLES |
AP Meeson, M Argilla, K Ko, L Witte and RA Lang
Skirball Institute for Biomolecular Medicine, Developmental Genetics Program, Cell Biology and Pathology Departments, New York University Medical Center, New York, NY10016, USA. lang@saturn.med.nyu.edu
The pupillary membrane (PM) is a transient ocular capillary network, which can serve as a model system in which to study the mechanism of capillary regression. Previous work has shown that there is a tight correlation between the cessation of blood flow in a capillary segment and the appearance of apoptotic capillary cells throughout the segment. This pattern of cell death is referred to as synchronous apoptosis (Lang, R. A., Lustig, M., Francois, F., Sellinger, M. and Plesken, H. (1994) Development 120, 3395-3404; Meeson, A., Palmer, M., Calfon, M. and Lang, R. A. (1996) Development 122, 3929-3938). In the present study, we have investigated whether the cause of synchronous apoptosis might be a segmental deficiency of either oxygen or a survival factor. Labeling with the compound EF5 in a normal PM indicated no segmental hypoxia; this argued that oxygen deprivation was unlikely to be the cause of synchronous apoptosis. When rat plasma was used as a source of survival factors in an in vitro PM explant assay, inhibition of vascular endothelial growth factor (VEGF) all but eliminated the activity of plasma in suppressing apoptosis. This argued that VEGF was an important plasma survival factor. Furthermore, inhibition of VEGF in vivo using fusion proteins of the human Flk-1/KDR receptor resulted in a significantly increased number of capillaries showing synchronous apoptosis. This provides evidence that VEGF is necessary for endothelial cell survival in this system and in addition, that VEGF deprivation mediated by flow cessation is a component of synchronous apoptosis.
This article has been cited by other articles:
![]() |
O. Tatar, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, A. Adam, K. Shinoda, C. Eckardt, V. Boeyden, C. Claes, G. Pertile, et al. Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization Arch Ophthalmol, June 1, 2008; 126(6): 782 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-J. Mourad, G. des Guetz, H. Debbabi, and B. I. Levy Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation Ann. Onc., May 1, 2008; 19(5): 927 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rao, I. B. Lobov, J. E. Vallance, K. Tsujikawa, I. Shiojima, S. Akunuru, K. Walsh, L. E. Benjamin, and R. A. Lang Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch Development, December 15, 2007; 134(24): 4449 - 4458. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jacquier, C. B. Higgins, A. J. Martin, L. Do, D. Saloner, and M. Saeed Injection of Adeno-associated Viral Vector Encoding Vascular Endothelial Growth Factor Gene in Infarcted Swine Myocardium: MR Measurements of Left Ventricular Function and Strain Radiology, October 1, 2007; 245(1): 196 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Hao, A. Mansson-Broberg, K.-H. Grinnemo, A. J. Siddiqui, G. Dellgren, L. A. Brodin, and C. Sylven Myocardial angiogenesis after plasmid or adenoviral VEGF-A165 gene transfer in rat myocardial infarction model Cardiovasc Res, February 1, 2007; 73(3): 481 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
R B Bhisitkul Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol., December 1, 2006; 90(12): 1542 - 1547. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Morizane, S. Mohri, J. Kosaka, S. Tone, T. Kiyooka, T. Miyasaka, J. Shimizu, Y. Ogasawara, F. Shiraga, Y. Minatogawa, et al. Iris movement mediates vascular apoptosis during rat pupillary membrane regression Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R819 - R825. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hiratsuka, K. Nakao, K. Nakamura, M. Katsuki, Y. Maru, and M. Shibuya Membrane Fixation of Vascular Endothelial Growth Factor Receptor 1 Ligand-Binding Domain Is Important for Vasculogenesis and Angiogenesis in Mice Mol. Cell. Biol., January 1, 2005; 25(1): 346 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, et al. Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts Am. J. Pathol., July 1, 2004; 165(1): 35 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Liu, J. Selever, D. Wang, M.-F. Lu, K. A. Moses, R. J. Schwartz, and J. F. Martin Bmp4 signaling is required for outflow-tract septation and branchial-arch artery remodeling PNAS, March 30, 2004; 101(13): 4489 - 4494. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-B. Shui, X. Wang, J. S. Hu, S.-P. Wang, C. M. Garcia, J. D. Potts, Y. Sharma, and D. C. Beebe Vascular Endothelial Growth Factor Expression and Signaling in the Lens Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3911 - 3919. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kiyono and M. Shibuya Bone Morphogenetic Protein 4 Mediates Apoptosis of Capillary Endothelial Cells during Rat Pupillary Membrane Regression Mol. Cell. Biol., July 1, 2003; 23(13): 4627 - 4636. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. B. Lobov, P. C. Brooks, and R. A. Lang From the Cover: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo PNAS, August 20, 2002; 99(17): 11205 - 11210. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ohashi, A. Shimizu, Y. Masuda, H. Kitamura, M. Ishizaki, Y. Sugisaki, and N. Yamanaka Peritubular Capillary Regression during the Progression of Experimental Obstructive Nephropathy J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1795 - 1805. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Liu, W. Liu, J. Palie, M. F. Lu, N. A. Brown, and J. F. Martin Pitx2c patterns anterior myocardium and aortic arch vessels and is required for local cell movement into atrioventricular cushions Development, January 11, 2002; 129(21): 5081 - 5091. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vinals and J. Pouyssegur Transforming Growth Factor {beta}1 (TGF-{beta}1) Promotes Endothelial Cell Survival during In Vitro Angiogenesis via an Autocrine Mechanism Implicating TGF-{alpha} Signaling Mol. Cell. Biol., November 1, 2001; 21(21): 7218 - 7230. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Conway, D. Collen, and P. Carmeliet Molecular mechanisms of blood vessel growth Cardiovasc Res, February 16, 2001; 49(3): 507 - 521. [Full Text] [PDF] |
||||
![]() |
K. C. Meyer, A. L. Cardoni, Z. Xiang, R. D. Cornwell, and R. B. Love Vascular Endothelial Growth Factor in Human Lung Transplantation Chest, January 1, 2001; 119(1): 137 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Fisher, B. L. Langille, and D. Srivastava Apoptosis During Cardiovascular Development Circ. Res., November 10, 2000; 87(10): 856 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inoue, J. W. Slaton, D. W. Davis, D. J. Hicklin, D. J. McConkey, T. Karashima, R. Radinsky, and C. P. N. Dinney Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel Clin. Cancer Res., July 1, 2000; 6(7): 2635 - 2643. [Abstract] [Full Text] |
||||